A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1391-1396

  Lacy, John M ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

5 reductase inhibitors; Chemoprevention; Clinical trials; PCPT; Prostate cancer; REDUCE

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; SELENIUM; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TOREMIFENE;

CHEMOPROPHYLAXIS; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84923068279     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2388     Document Type: Review

References (32)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Wachtel MS, Nelius, T, Haynes AL, Dahlbeck S and de Riese W: PSA screening and deaths from prostate cancer after diagnosis-a population bases analysis. Prostate 73: 1365-1369, 2013.
3. Moyer VA; U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157: 120-134, 2012.
4. Sandhu GS, Nepple KG, Tanagho YS and Andriole GL: Prostate cancer chemoprevention. Semin Oncol 40: 276-285, 2013.
5. Klein EA, Thompson IM Jr, Tangen CM, et al: Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549-1556, 2011.
6. Schwartz GG: Vitamin D, sunlight, and the epidemiology of prostate cancer. Anticancer Agents Med Chem 13: 45-57, 2013.
7. No authors listed: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330: 1029-1035, 1994.
8. Raghow S, Hooshdaran MZ, Katiyar S and Steiner MS: Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62: 1370-1376, 2002.
9. Roberts RO, Jacobson DJ, Girman CJ, et al: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77: 219-225, 2002.
10. Irani J, Ravery V, Pariente JL, et al: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 168: 1985-1988, 2002.
11. Bonovas S, Filioussi K and Sitaras NM: Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123: 899-904, 2008.
12. Thomas JA II, Gerber L, Moreira DM, et al: Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med 272: 85-92, 2012.
13. Coffey DS and Walsh PC: Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17: 461-475, 1990.
14. Steers WD: 5alpha-reductase activity in the prostate. Urology 58: 17-24, 2001.
15. Platz EA and Giovannucci E: The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92: 237-253, 2004.
16. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224, 2003.
17. Andriole G, Bostwick D, Brawley O, et al: Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (4 Pt 1): 1314-1317, 2004.
18. Andriole GL, Bostwick DG, Brawley OW, et al: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192-1202, 2010.
19. Redman MW, Tangen CM, Goodman PJ, et al: Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 1: 174-181, 2008.
20. Roehrborn CG, Boyle P, Bergner D, et al: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 54: 662-669, 1999.
21. Pinsky P, Parnes H and Ford L: Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila) 1: 182-186, 2008.
22. Cohen YC, Liu KS, Heyden NL, et al: Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99: 1366-1374, 2007.
23. Kaplan SA, Roehrborn CG, Meehan AG, et al: PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate-and high-grade (Gleason score 6 and 7) cancer. Urology 73: 935-939, 2009.
24. Borden LS Jr, Wright JL, Kim J, Latchamsetty K and Porter CR: An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int 99: 559-563, 2007.
25. Choo R, Danjoux C, Morton G, et al: How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 67: 1614-1620, 2007.
26. Pinsky PF, Black A, Grubb R, et al: Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer 119: 593-601, 2013.
27. Thompson IM Jr, Goodman PJ, Tangen CM, et al: Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369: 603-610, 2013.
28. Grubb RL, Andriole GL, Somerville MC, et al: The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial. J Urol 189: 871-877, 2013.
29. Theoret MR, Ning YM, Zhang JJ, et al: The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med 365: 97-99, 2011.
30. Fleshner NE, Lucia MS, Egerdie B, et al: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 379: 1103-1111, 2012.
31. Kattan MW, Earnshaw SR, McDade CL, Black LK and Andriole GL: Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy 9: 305-315, 2011.
32. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM and Lotan Y: Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 112: 1058-1065, 2008.